Metraipolis › archive › dc_1fd2deefa69a

The impact of the 2019 revision of China's drug administration law on the innovative output of pharmaceutical and biotechnology enterprises-a quasi-natural… — Europe PMC PMID:41994443

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41994443
DOI
10.3389/fmed.2026.1592775
License (as archived)
solo-consultazione
Archived
2026-10-07T14:38:29.801Z
SHA-256 of the archived text
439f077eda0b32167194376c32a7b6b17ed0067ee9ac9666d91865b29ae9f158
Stable URL of this page
https://metraipolis.com/documento/dc_1fd2deefa69a

How to cite

The impact of the 2019 revision of China's drug administration law on the innovative output of pharmaceutical and biotechnology enterprises-a quasi-natural… — Europe PMC PMID:41994443 — Europe PMC (en), https://europepmc.org/article/MED/41994443 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1fd2deefa69a (Metraipolis archive dc_1fd2deefa69a, sha256 439f077eda0b32167194376c32a7b6b17ed0067ee9ac9666d91865b29ae9f158)
BibTeX
@misc{dc1fd2deefa69a,
  title = {The impact of the 2019 revision of China's drug administration law on the innovative output of pharmaceutical and biotechnology enterprises-a quasi-natural… — Europe PMC PMID:41994443},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41994443},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1fd2deefa69a; sha256 439f077eda0b32167194376c32a7b6b17ed0067ee9ac9666d91865b29ae9f158},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41994443. Agents can read the archived copy with the MCP tool read_document.